Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pet Pharm Biotech CoROCO:7762 -1.82%26 EV-to-EBITDA is 38.00 as of Sep. 15, 2026, which is 27% below its 10-year median of 51.73. GuruFocus rates ROCO:7762 with a GF Score™ of 26/100. The stock has 5 warning signs investors should review. Among 728 Drug Manufacturers companies, Pet Pharm Biotech Co ranks worse than 84.89% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pet Pharm Biotech Co's enterprise value is NT$2,893.1 Mil.
Pet Pharm Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$76.1 Mil. Therefore, Pet Pharm Biotech Co's EV-to-EBITDA for today is 38.00.
The historical rank and industry rank for Pet Pharm Biotech Co's EV-to-EBITDA or its related term are showing as below:
ROCO:7762'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 23.91 Med: 51.73 Max: 101.96
Current: 38
During the past 4 years, the highest EV-to-EBITDA of Pet Pharm Biotech Co was 101.96. The lowest was 23.91. And the median was 51.73.
ROCO:7762's EV-to-EBITDA is ranked worse than 84.89% of 728
companies
in the Drug Manufacturers industry
Industry Median: 13.375
vs ROCO:7762: 38.00
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Pet Pharm Biotech Co (ROCO:7762) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pet Pharm Biotech Co's PE Ratio (TTM) for today is calculated as:
Pet Pharm Biotech Co's share price for today is NT$54.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pet Pharm Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$0.516.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Pet Pharm Biotech Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7762 vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pet Pharm Biotech Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pet Pharm Biotech Co's EV-to-EBITDA falls into.
Pet Pharm Biotech Co's current Enterprise Value is NT$2,893.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pet Pharm Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$76.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pet Pharm Biotech Co (ROCO:7762) has a EV-to-EBITDA of 38.00 as of Sep. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Pet Pharm Biotech Co. This is 27% below median its historical median of 51.73. Over the past decade, Pet Pharm Biotech Co's EV-to-EBITDA has ranged from 23.91 to 101.96. According to the industry distribution chart, Pet Pharm Biotech Co ranks #618 out of 728 companies in the Drug Manufacturers industry, placing it in the top 84.9%.
Is Pet Pharm Biotech Co's EV-to-EBITDA too high?
Pet Pharm Biotech Co's current EV-to-EBITDA of 38.00 is 27% below median its 10-year median of 51.73. Over the past 10 years, this metric has ranged from a low of 23.91 to a high of 101.96. The Drug Manufacturers industry median EV-to-EBITDA is 13.38. Pet Pharm Biotech Co's value of 38.00 is 184.1% above this industry median. Based on the distribution chart, Pet Pharm Biotech Co ranks #618 out of 728 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Pet Pharm Biotech Co has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Pet Pharm Biotech Co ranks #618 out of 728 companies for EV-to-EBITDA. This places Pet Pharm Biotech Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.38. Pet Pharm Biotech Co's value of 38.00 is 184.1% above this benchmark. Historically, Pet Pharm Biotech Co's own EV-to-EBITDA has ranged from 23.91 to 101.96 over the past decade. While the company's 10-year median is 51.73 vs. the industry median of 13.38, Pet Pharm Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.38, based on 728 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pet Pharm Biotech Co's current EV-to-EBITDA of 38.00 is 184.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Pet Pharm Biotech Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pet Pharm Biotech Co's current EV-to-EBITDA is 38.00, which is 27% below median its own 10-year median of 51.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current EV-to-EBITDA of 38.00. The current EV-to-EBITDA is 38.00, which is 27% below median its 10-year median of 51.73 and 184.1% above the Drug Manufacturers industry median of 13.38. Pet Pharm Biotech Co's overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current EV-to-EBITDA is 38.00 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
26GF Score
Get the complete analysis for ROCO:7762
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7762 has been successfully added to your 
